Xtx Topco LTD Vertex Pharmaceuticals Inc Transaction History

Xtx Topco LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$392.81 - $485.53 $3.32 Million - $4.1 Million	8,449 New	8,449 $3.96 Million
Q4 2023 Feb 13, 2024	SELL	$343.0 - $410.68 $1.49 Million - $1.79 Million	-4,351 Reduced 61.55%	2,718 $1.11 Million
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $1.44 Million - $1.55 Million	4,270 Added 152.55%	7,069 $2.46 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $367,871 - $411,734	1,170 Added 71.82%	2,799 $984,000
Q1 2023 May 12, 2023	BUY	$283.23 - $323.1 $219,220 - $250,079	774 Added 90.53%	1,629 $513,000
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $301,191 - $338,839	-1,054 Reduced 55.21%	855 $246,000
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $264,793 - $295,447	967 Added 102.65%	1,909 $553,000
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $291,115 - $362,469	-1,239 Reduced 56.81%	942 $265,000
Q1 2022 May 13, 2022	SELL	$221.42 - $260.97 $237,583 - $280,020	-1,073 Reduced 32.97%	2,181 $569,000
Q4 2021 Feb 11, 2022	BUY	$177.01 - $223.45 $575,990 - $727,106	3,254 New	3,254 $715,000

1,722

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

Stay updated on Xtx Topco LTD with notifications on news.